Literature DB >> 2679842

The endocrine prevention of breast cancer.

I S Fentiman1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2679842      PMCID： PMC2247347          DOI： 10.1038/bjc.1989.210

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  14 in total

1.  Endocrine consequences of continuous antiestrogen therapy with tamoxifen in premenopausal women.

Authors:  B M Sherman; F K Chapler; K Crickard; D Wycoff
Journal:  J Clin Invest       Date:  1979-08       Impact factor: 14.808

2.  Effect of the anti-oestrogen tamoxifen on plasma levels of luteinizing hormone, follicle-stimulating hormone, prolactin, oestradiol and progesterone in normal pre-menopausal women.

Authors:  G V Groom; K Griffiths
Journal:  J Endocrinol       Date:  1976-09       Impact factor: 4.286

3.  Binding of oestradiol to blood proteins and aetiology of breast cancer.

Authors:  J W Moore; G M Clark; S A Hoare; R R Millis; J L Hayward; M K Quinlan; D Y Wang; R D Bulbrook
Journal:  Int J Cancer       Date:  1986-11-15       Impact factor: 7.396

4.  The epidemiology and etiology of breast cancer.

Authors:  A B Miller; R D Bulbrook
Journal:  N Engl J Med       Date:  1980-11-20       Impact factor: 91.245

5.  Dosage and duration of tamoxifen treatment for mastalgia: a controlled trial.

Authors:  I S Fentiman; M Caleffi; H Hamed; M A Chaudary
Journal:  Br J Surg       Date:  1988-09       Impact factor: 6.939

6.  Genetic predisposition to breast cancer.

Authors:  H T Lynch; W A Albano; B S Danes; M A Layton; W J Kimberling; J F Lynch; S C Cheng; K A Costello; G M Mulcahy; C A Wagner
Journal:  Cancer       Date:  1984-02-01       Impact factor: 6.860

7.  Tamoxifen and benign breast problems.

Authors:  I S Fentiman; T J Powles
Journal:  Lancet       Date:  1987-11-07       Impact factor: 79.321

8.  Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen.

Authors:  S Rössner; A Wallgren
Journal:  Atherosclerosis       Date:  1984-09       Impact factor: 5.162

9.  Risk factors for breast cancer in women with proliferative breast disease.

Authors:  W D Dupont; D L Page
Journal:  N Engl J Med       Date:  1985-01-17       Impact factor: 91.245

10.  LHRH agonists and the prevention of breast and ovarian cancer.

Authors:  M C Pike; R K Ross; R A Lobo; T J Key; M Potts; B E Henderson
Journal:  Br J Cancer       Date:  1989-07       Impact factor: 7.640
View more
  3 in total

Review 1.  Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.

Authors:  P E Lønning; E A Lien; S Lundgren; S Kvinnsland
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

2.  4-Hydroxyandrostenedione in the prophylaxis of N-methyl-N-nitrosourea induced mammary tumourigenesis.

Authors:  R C Coombes; J R Wilkinson; J M Bliss; P Shah; D F Easton; M Dowsett
Journal:  Br J Cancer       Date:  1991-08       Impact factor: 7.640

3.  Influence of the antioestrogen tamoxifen on normal breast tissue.

Authors:  K J Walker; J M Price-Thomas; W Candlish; R I Nicholson
Journal:  Br J Cancer       Date:  1991-10       Impact factor: 7.640
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.